1. An assessment by the Statin Diabetes Safety Task Force: 2014 update
Kevin C. Maki, PhD, FNLA, Paul M. Ridker, MD, MPH, W. Virgil Brown, MD, FNLA, Scott M. Grundy, MD, PhD, FNLA, Naveed Sattar, MD, PhD 
Journal of Clinical Lipidology 
Volume 8, Issue 3, Pages S17-S29 (May 2014)
DOI: /j.jacl
Copyright © 2014 National Lipid Association Terms and Conditions

2. Figure 1
Association between statin therapy and incident diabetes in 13 major cardiovascular trials. AFCAPS/TEXCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm; CI, confidence interval; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; GISSI HF, Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca; GISSI PREV, Gruppo Italiano per lo Studio della Sopravvivenza nell Insufficienza Prevenzione; HPS, Heart Protection Study; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LIPID, Long-term Intervention with Pravastatin in Ischemic Disease; MEGA, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; OR, odds ratio; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; 4S, Scandinavian Simvastatin Survival Study; WOSCOPS, West of Scotland Coronary Prevention Study.
Permission to reuse this figure was granted by Elsevier.13
Journal of Clinical Lipidology 2014 8, S17-S29DOI: ( /j.jacl )
Copyright © 2014 National Lipid Association Terms and Conditions

3. Figure 2
Risk of developing new-onset diabetes and CV events according to the number of diabetes risk factors at baseline in the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering statin trials. Atorva, atorvastatin; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; simva, simvastatin.
Permission to reuse this figure was granted by Elsevier.18
Journal of Clinical Lipidology 2014 8, S17-S29DOI: ( /j.jacl )
Copyright © 2014 National Lipid Association Terms and Conditions